These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1776 related items for PubMed ID: 16330290

  • 1. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL, Stewart J, Issa M, Lake B, Melis R.
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [Abstract] [Full Text] [Related]

  • 2. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [Abstract] [Full Text] [Related]

  • 3. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [Abstract] [Full Text] [Related]

  • 4. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [Abstract] [Full Text] [Related]

  • 5. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D, Touger MS, Melis R, Schleusener DS, McCluskey D.
    Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
    [Abstract] [Full Text] [Related]

  • 6. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J, Bugos C, Dirnberger G, Atherton T.
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [Abstract] [Full Text] [Related]

  • 10. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
    Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF.
    Diabetes Obes Metab; 2006 Mar; 8(2):197-205. PubMed ID: 16448524
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 14. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.
    Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
    [Abstract] [Full Text] [Related]

  • 15. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF, Traylor L, Schwartz SL.
    Endocr Pract; 2010 May; 16(4):588-99. PubMed ID: 20350924
    [Abstract] [Full Text] [Related]

  • 16. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.
    Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.
    Ann Intern Med; 2001 May 01; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [Abstract] [Full Text] [Related]

  • 19. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.
    J Clin Pharm Ther; 2006 Aug 01; 31(4):375-83. PubMed ID: 16882108
    [Abstract] [Full Text] [Related]

  • 20. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
    Rajagopalan R, Xu Y, Abbadessa M, Quartet Study Group.
    Am J Geriatr Pharmacother; 2006 Jun 01; 4(2):123-33. PubMed ID: 16860259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 89.